RxDoctor Payments Data

Ronald Trudel, MD

Internal Medicine · Salt Lake City, UTNPI 1962455626

Payments from drug & device makers

$1,347in general payments, 2019–2025

Across 67 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$294
  • AbbVie$218
  • Astellas Pharma US Inc$187
  • E.r. Squibb & Sons, L.L.C.$114
  • Eisai Inc.$87
  • Amgen$72
  • plus $376 from 12 others

What the payments were for

  • Food & beverage$1,29796%
  • Education$504%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,347 in reported general payments places this provider in the 75th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$123,543
Medicare patients
263
Services billed
1,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$83,889
TrulicityDulaglutide43$43,859
MounjaroTirzepatide30$31,610
XareltoRivaroxaban31$29,535
RybelsusSemaglutide22$29,261
MyrbetriqMirabegron18$21,294
OzempicSemaglutide20$20,016
CreonLipase/Protease/Amylase31$15,887
Tresiba Flextouch U-100Insulin Degludec11$15,428
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$15,204
JardianceEmpagliflozin15$13,999
GemtesaVibegron25$12,744
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,378
Linezolid11$9,601
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$8,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$32$75,47073 claims
Novo NordiskRybelsus, Ozempic$294$49,27742 claims
AbbVieCreon, Linzess$218$22,42043 claims
Astellas Pharma US IncMyrbetriq$187$21,29418 claims
Sumitomo Pharma America, Inc.Gemtesa$24$12,74425 claims
AstraZenecaBreztri Aerosphere$64$10,37817 claims
GSKIncruse Ellipta$12$4,62014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →